Home > Boards > US OTC > Biotechs > International Stem Cell Corp. (ISCO)

SS:Series B Convertible Preferred stock, $0.001 par value,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
axelvento Member Profile
 
Followed By 39
Posts 5,381
Boards Moderated 0
Alias Born 10/25/07
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 8/27/2019 6:01:43 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/14/2019 5:07:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2019 3:44:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 2:56:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 1:48:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 1:47:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:05:35 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2019 6:31:48 AM
International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial InvestorsHub NewsWire - 4/29/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 4:33:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2019 2:13:50 PM
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results InvestorsHub NewsWire - 4/16/2019 8:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/15/2019 6:13:56 AM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/1/2019 4:32:13 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/7/2019 6:05:53 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2019 4:42:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2019 4:42:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2019 4:41:47 PM
International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury InvestorsHub NewsWire - 2/13/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/23/2019 4:27:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/22/2019 6:16:40 PM
International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business InvestorsHub NewsWire - 1/15/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/6/2018 8:04:03 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/6/2018 8:01:22 AM
International Stem Cell Corporation is Valued at $6.16 per Share by Edison Investment Research InvestorsHub NewsWire - 12/5/2018 8:30:00 AM
axelvento   Tuesday, 10/09/18 12:47:15 AM
Re: None
Post # of 6562 
SS:

Series B Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, 250,000
issued and outstanding, with liquidation preferences of $402 and $396 at June 30, 2018
and December 31, 2017, respectively








Series D Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and
outstanding, with liquidation preference of $4,320








Series G Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized,
issued and outstanding, with liquidation preference of $5,000


5



5

Series I-1 Convertible Preferred stock, $0.001 par value, 2,000 shares authorized, 1,094 and
1,304 issued and outstanding, with liquidation preferences of $1,094 and $1,304 at
June 30, 2018 and December 31, 2017, respectively







Series I-2 Convertible Preferred stock, $0.001 par value, 4,310 shares authorized,
issued and outstanding with liquidation preference of $4,310







Common stock, $0.001 par value, 120,000,000 shares authorized, 6,295,888 and 6,057,132
shares issued and outstanding at June 30, 2018 and December 31, 2017,



"Six patients have now fully completed the study and entered the follow-up phase while two other patients have completed the six-month evaluation. The treatment phase of the study will conclude following the dosing of the last two patients of the third cohort, which ISCO plans to complete soon."

The surgery, which was performed by a team of neurosurgeons at the Royal Melbourne Hospital in Melbourne, Australia, proceeded without complications and the patient was discharged soon after.

https://www.thermh.org.au/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist